Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

Huntington Beach, California and Amsterdam (ots/PRNewswire) -
Agendia, a world leader in molecular cancer diagnostics, today
announced that leading researchers from Agendia, the University of
California San Francisco and the Netherlands Cancer Institute will
present data from multiple studies at the American Society of
Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando,
Florida.

The study results further underpin the broad predictive and
prognostic power of Agendia's breast cancer recurrence test
MammaPrint(R) and highlight promising data on Agendia's new colon
cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia
team in booth #2014 and study results will be discussed at the
following sessions:

Date: Saturday, May 30, 2009
ORAL PRESENTATION
Abstract #512
Time: 5:00PM - 5:15PM
Location: Level 2, West Hall D1
The 70-gene profile and chemotherapy benefit in 1,600 breast cancer
patients
R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C.
Linn, L. J. Van 't Veer
Date: Saturday, May 30, 2009
ORAL PRESENTATION
Abstract # LBA515
Time: 3:00PM - 6:00PM
Location: Level 2, West Hall D1
Breast cancer molecular profiles predict tumor response of neoadjuvant
Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't
Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators
Date: Saturday, May 30, 2009
POSTER PRESENTATION
Abstract #6570
Time: 2:00PM - 6:00PM
Location: Level 2, West Hall C
Cost effectiveness of targeting chemotherapy with the 70-gene
prognostic signature in early stage breast cancer (ESBC) patients
K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin
Date: Sunday, May 31, 2009
POSTER DISCUSSION
Abstract #535
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Outcome prediction by the 70-gene profile in the context of the National
Comprehensive Cancer Network (NCCN) guideline
F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
A. M. Glas, S. C. Linn, L. J. Van 't Veer
Date: Sunday, May 31, 2009
POSTER PRESENTATION
Abstract #4036
Time: 8:00 AM - 12:00 PM
Location: Level 2, West Hall C
Development and validation of a robust prognostic and predictive
signature for colorectal cancer (CRC) patients
A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar
Date: Sunday, May 31, 2009
POSTER DISCUSSION
Abstract #518
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Early determination of metastatic potential in breast cancer: the 70-gene
signature in small tumors
M. Knauer, S. Mook, V. Retèl, M. Kok, J. Wesseling, A. M. Glas, E. J.
Rutgers, L. J. van 't Veer, S. C. Linn
Date: Monday, June 01, 2009
POSTER PRESENTATION
Abstract #11083
Time: 1:00PM - 5:00PM
Location: Level 2, West Hall C
Combining multi-gene profiling of molecular subtypes with the 70-gene
profile for classification of breast cancer
L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender,
A. M. Glas

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index
assay' (IVDMIA) cleared by the U.S. Food and Drug Administration
(FDA). FDA clearance requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early
metastasis-patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results provide doctors with
a clear rationale to assess the benefit of chemotherapy in addition
to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited
service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous
FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. The Company was awarded the 2008 North American Oncology
Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan.
Agendia is based in Huntington Beach, California, and in Amsterdam,
The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media contacts: Hans Herklots, Agendia, +31-20-462-1557 Office,
+31-620-083-509 Mobile, hans.herklots@agendia.com. Valerie Delva,
Ricochet Public Relations, +1-212-679-3300 x131 Office,
+1-917-975-3191 Mobile, vdelva@ricochetpr.com